Populations and Risk Factors
- Any cancer patient may receive radiation; most common in breast, prostate, lung, head/neck, and cervical cancers
- Breast cancer patients receiving axillary or supraclavicular field radiation face compounded lymphedema risk (surgery + radiation to the same nodal chain)
- Head and neck cancer patients: severe mucositis, xerostomia, fibrosis of jaw and cervical muscles
- Patients with connective tissue disorders (scleroderma, lupus) may have exaggerated tissue reactions
- Older patients and those with diabetes may have delayed healing of radiation skin reactions
- Previous radiation to the same field increases cumulative tissue damage
- Concurrent chemotherapy (chemoradiation) amplifies side effects including skin reactions and fibrosis
Causes and Pathophysiology
Mechanism of Action
- Radiation damages cellular DNA through direct ionization and indirect free radical generation (primarily from water radiolysis).
- Cancer cells are more vulnerable because they divide rapidly and have impaired DNA repair mechanisms compared to normal cells.
- However, all cells in the radiation field receive the dose — normal tissues are affected proportionally, producing the predictable side effects described below.
Acute Radiation Effects (During Treatment and Weeks After)
- Radiation dermatitis progresses through predictable stages within the treatment field:
- Erythema — redness similar to sunburn; develops within the first 2 weeks
- Dry desquamation — peeling, flaking, pruritic skin; epidermis shedding
- Moist desquamation — open, weeping skin where the epidermis has sloughed completely; painful; infection risk; may occur in skin folds (axilla, inframammary fold)
- Fatigue: cumulative radiation fatigue builds throughout the treatment course and peaks 1–2 weeks after the final fraction; qualitatively different from chemotherapy fatigue — more gradual and persistent
- Mucositis and xerostomia: head/neck radiation destroys salivary glands and oral mucosa
Chronic Radiation Effects (Months to Years Post-Treatment)
- Radiation fibrosis is the dominant long-term clinical concern — ionizing radiation triggers a chronic fibroblast response that deposits dense collagen in the irradiated tissues.
- Fibrosis develops gradually over months to years post-treatment and is progressive.
- Affected tissues become dense, contracted, and inelastic — resembling chronic scar tissue.
- Fibrosis in chest wall and axillary tissues (breast cancer fields) restricts shoulder ROM, particularly flexion, abduction, and external rotation.
- Fibrosis in cervical and jaw tissues (head/neck fields) causes trismus (limited mouth opening) and restricted cervical rotation.
- Brachial plexopathy: radiation to the axillary and supraclavicular fields (breast cancer, lung cancer) can damage the brachial plexus, producing progressive weakness, numbness, and pain in the arm — may be difficult to distinguish from tumor recurrence (radiation-induced plexopathy is typically painless initially and affects the upper trunk C5–C6; tumor recurrence is typically painful and affects the lower trunk C8–T1).
- Lymphedema: radiation damages lymphatic vessels and nodes, reducing lymphatic transport capacity; the risk is lifelong and additive with surgical node removal.
- Bone fragility: irradiated bone undergoes vascular damage (avascular necrosis), reduced osteoblast activity, and progressive weakening; higher fracture risk, particularly in ribs, sternum, and proximal humerus after breast/chest radiation.
- Secondary malignancy: small but real long-term risk of radiation-induced cancer within the treatment field, typically appearing years to decades later.
Radiation Recall
- Certain chemotherapy drugs (doxorubicin, taxanes, gemcitabine) can trigger an inflammatory reaction in a previously irradiated field weeks to months after radiation treatment has ended.
- Presents as erythema, swelling, and sometimes desquamation in the exact pattern of the original radiation field.
- This is a local contraindication until resolved.
Signs and Symptoms
During Active Treatment
- Erythema in the treatment field (redness matching the beam entry and exit points)
- Skin peeling and flaking (dry desquamation)
- Open, weeping, painful skin (moist desquamation) — particularly in skin folds
- Ink marks or small tattoo dots on the skin indicating field boundaries — these must never be removed
- Progressive cumulative fatigue worsening throughout the treatment course
- Localized hair loss within the field only
Post-Treatment (Chronic Phase)
- Dense, contracted, inelastic tissue within the radiation field (radiation fibrosis)
- Restricted ROM at joints crossed by the fibrotic field (e.g., shoulder flexion/abduction after breast/axillary radiation)
- Skin texture changes: thickened, discolored, telangiectasias (visible small blood vessels)
- Lymphedema in downstream limbs if nodal chains were irradiated
- Arm weakness, numbness, or pain (brachial plexopathy — breast/axillary fields)
- Trismus and cervical stiffness (head/neck fields)
- Rib tenderness or fracture risk in the irradiated field
Assessment Profile
Subjective Presentation
- Chief complaint: during treatment — "my skin is sore and red where they're giving the radiation" or "I'm exhausted — the fatigue keeps building"; post-treatment — "my chest/neck feels stiff and tight where I had radiation" or "I can't lift my arm as high as I used to" or "my arm is swelling"
- Pain quality: during treatment — burning, raw, stinging at the skin surface in the field; post-treatment — deep tightness, pulling, restricted feeling from fibrosis; neuropathic pain (burning, shooting) if brachial plexopathy develops; dull aching from lymphedema
- Onset: skin reactions develop within 1–2 weeks of starting treatment and progress; fibrosis develops months to years after treatment and is progressive; lymphedema may appear at any time post-treatment
- Aggravating factors: friction or pressure on the irradiated skin (during treatment); movement that stretches through fibrotic tissue (post-treatment); heat or sun exposure on irradiated skin; lubricants or topical products applied to the field during active treatment (may interfere with dosimetry)
- Easing factors: gentle skin care with approved products; moisturizing after radiation course is complete; gentle sustained stretching of fibrotic tissue; compression for lymphedema; cool compresses for skin comfort
- Red flags: Moist desquamation (open weeping skin) — local contraindication; medical management required. New onset of arm weakness, numbness, or progressive pain months to years after treatment — may indicate brachial plexopathy or tumor recurrence; medical referral for differentiation. Radiation recall reaction (erythema in a previously irradiated field during chemotherapy) — local contraindication; oncologic referral.
Observation
- Local inspection: identify the radiation field — look for ink marks, tattoo dots, erythema, skin texture changes, or visible fibrosis boundaries; assess skin integrity within the field (intact, peeling, open); note teleangiectasias and discoloration in mature fields; assess for lymphedema in downstream limbs; presence of compression garments
- Posture: compensatory patterns depend on the radiation field location — breast/axillary fields produce ipsilateral shoulder protraction, thoracic kyphosis; head/neck fields produce cervical flexion restriction and forward head posture; pelvic fields may produce hip stiffness
- Gait: typically normal unless pelvic or lower extremity radiation has caused fibrosis affecting hip or knee mobility; fatigue-related slow, cautious gait during active treatment
Palpation
- Tone: muscles within and adjacent to the radiation field develop adaptive stiffness from fibrosis; muscles compensating for fibrosis-related ROM loss become hypertonic (e.g., upper trapezius and levator scapulae compensating for restricted shoulder ROM after chest wall radiation)
- Tenderness: irradiated skin is tender during treatment and for weeks after; fibrotic tissue may be tender on deep palpation; rib tenderness within the field (fragile bone); brachial plexus tension or tenderness (if plexopathy present); compensatory muscle tenderness outside the field
- Temperature: active radiation dermatitis produces warmth at the field surface; mature fibrotic tissue may be normal or slightly cool (reduced vascularity); warmth within the field months after treatment suggests either radiation recall or infection — investigate before treating
- Tissue quality: the defining palpatory finding is radiation fibrosis — dense, inelastic, contracted tissue that does not glide normally; tissue layers are adhered (skin to fascia to muscle); palpation feels like pressing into a firm, woody substrate; contrast with the normal tissue mobility outside the field is diagnostic; lymphedematous tissue downstream from irradiated nodes shows soft pitting (early) or brawny non-pitting (late) quality
Motion Assessment
- AROM: restricted in directions where fibrotic tissue crosses a joint — shoulder flexion, abduction, and ER after breast/axillary radiation; cervical rotation and lateral flexion after head/neck radiation; restrictions are progressive (may worsen for years post-treatment without intervention); compare bilaterally
- PROM / end-feel: firm, inelastic (leathery to woody) end-feel within the fibrotic field — distinct from capsular restriction; fibrotic tissue yields very little to sustained load compared to scar tissue from surgery; PROM may only marginally exceed AROM (fibrotic tissue is resistant to stretch); end-feel occurs early in range and is unyielding
- Resisted testing: may reveal weakness in muscles innervated by the brachial plexus if plexopathy is present (C5–C6 weakness: deltoid, biceps; C8–T1 weakness: hand intrinsics, grip); weakness from fibrosis-related disuse may also be present; test systematically if neurological symptoms are reported
Special Test Cluster
The SOT cluster for radiation therapy is oriented toward assessing field boundaries, skin integrity, fibrosis severity, and screening for complications rather than standard orthopedic diagnosis.| Test | Positive Finding | Purpose |
|---|---|---|
| Radiation Field Identification (Visual/History) (CMTO) | Identify field boundaries by ink marks, tattoos, skin changes, and treatment history | Determine local contraindication zone during treatment and fibrosis treatment zone post-healing |
| Skin Integrity Assessment (CMTO) | Erythema, dry desquamation, moist desquamation, or open skin within the field | Determine whether local massage is contraindicated (open/weeping skin) or requires modification (intact but fragile skin) |
| ROM Measurement (Goniometry) (CMTO) | Restricted ROM at joints crossed by the radiation field | Quantify fibrosis-related restriction; track progression and treatment response |
| Lymphedema Screen (Girth Measurement, Stemmer Sign) (CMTO) | Limb asymmetry >2 cm; positive Stemmer sign | Identify lymphedema in limbs downstream from irradiated nodal chains |
| Brachial Plexus Screen (Strength, Sensation) (supplementary) | Upper extremity weakness or sensory loss in specific nerve root distributions; particularly C5–C6 (upper trunk) | Detect radiation-induced brachial plexopathy; distinguish from tumor recurrence (upper trunk = radiation; lower trunk = tumor) |
| Bone Tenderness Assessment (Field Palpation) (supplementary) | Point tenderness over irradiated ribs, sternum, or other bones in the field | Screen for radiation-related bone fragility or occult fracture; guides pressure modification |
Brachial plexopathy differential: Radiation-induced plexopathy typically affects the upper trunk (C5–C6), is initially painless, and progresses slowly. Tumor recurrence typically affects the lower trunk (C8–T1), is painful from the onset, and progresses more rapidly. Both require medical investigation — refer when neurological symptoms are new or changing.
Differential Assessment
| Condition | Key Distinguishing Feature |
|---|---|
| Tumor Recurrence (Local) | New hard mass in or near the radiation field; progressive pain; lower brachial plexus involvement (C8–T1); urgent oncologic referral |
| Radiation Recall | Inflammatory reaction in the radiation field triggered by chemotherapy weeks to months after radiation ended; erythema matches the exact field pattern; local contraindication until resolved; oncologic referral |
| Adhesive Capsulitis | Capsular pattern of restriction (ER most limited); may coexist with radiation fibrosis; distinguished by capsular end-feel and distribution of restriction following the capsular pattern rather than the radiation field boundaries |
| Lymphedema | Limb swelling downstream from irradiated nodes; may coexist with fibrosis; positive Stemmer sign confirms Stage II+; requires MLD approach separate from fibrosis management |
| Post-Surgical Scar Restriction | Scar adhesion follows the surgical incision line rather than the radiation field; scar tissue is typically more pliable than radiation fibrosis and responds more readily to mobilization |
CMTO Exam Relevance
- The radiation field is a local contraindication during active treatment and until the skin fully heals (typically 2–6 weeks post-treatment)
- Ink marks and targeting tattoos must never be removed or altered
- No lubricants applied to the radiation field without oncologist approval during active treatment
- Radiation fibrosis is a delayed long-term complication (months to years) causing progressive tissue density and ROM restriction
- Lymphedema risk is permanent after nodal irradiation — additive with surgical risk
- Irradiated bone has increased fracture risk — use conservative pressure over bones in the field
- Know the brachial plexopathy distinction: upper trunk (C5–C6) = radiation; lower trunk (C8–T1) = tumor recurrence
- Radiation recall can occur weeks to months after radiation ends, triggered by certain chemotherapy drugs
Massage Therapy Considerations
- Primary therapeutic target: post-treatment radiation fibrosis — restoring tissue mobility, pliability, and ROM in and around the irradiated field through gentle, sustained myofascial techniques; secondary targets include compensatory musculoskeletal tension and lymphedema management
- Sequencing logic: during active treatment, the field is off-limits — focus on general relaxation, compensatory tension, and fatigue management away from the field; post-healing, begin with surrounding tissue to prepare for field-adjacent work, then progressively address fibrotic tissue within the field; always assess skin integrity before any direct work
- Safety / contraindications: never massage the radiation field while treatment is active or skin is not fully healed; no lubricants over the field during active treatment without oncologist approval; irradiated bone has higher fracture risk — avoid deep pressure or joint mobilization directly over irradiated bones (ribs, sternum, pelvis); conservative pressure over the field even post-healing; if lymphedema is present, MLD principles apply to the downstream limb
- Heat/cold guidance: avoid heat over the radiation field during treatment (increases skin reaction); post-healing, warm moist heat may improve tissue pliability before gentle myofascial work on fibrotic tissue; cool compresses for comfort if skin is reactive; always confirm sensation is intact before thermal applications (radiation can alter nerve function)
- Brachytherapy specifics: no special radiation safety precautions for the therapist once removable implants are removed; permanent seed implants (prostate) pose no meaningful radiation exposure risk during brief treatment sessions
- Fatigue management: cumulative radiation fatigue is significant — keep sessions short during active treatment; monitor tolerance continuously; fatigue peaks 1–2 weeks after the final fraction
Treatment Plan Foundation
Clinical Goals
- Reduce radiation fibrosis density and restore tissue mobility within the irradiated field
- Maintain or improve ROM at joints affected by fibrosis-related restriction
- Manage compensatory musculoskeletal tension from altered posture and movement patterns
- Support lymphatic function in downstream limbs at risk for or affected by lymphedema
Position
- Position based on field location and comfort: semi-reclined supine for anterior chest/axillary fields; side-lying for lateral fields; seated for cervical/head and neck work
- Avoid pressure on the treatment field during active radiation — position to keep the field free
- Ensure the patient is warm — radiation fatigue often produces temperature sensitivity
Session Sequence
- General relaxation away from the radiation field — establish therapeutic rapport; address fatigue with slow, rhythmic techniques promoting parasympathetic activation
- Compensatory musculoskeletal tension — identify and treat muscles compensating for fibrosis-related restriction (e.g., upper trapezius, levator scapulae, contralateral trunk muscles); standard MT techniques appropriate in non-irradiated tissue
- Field-adjacent tissue preparation — effleurage and gentle myofascial release in the transition zone between normal tissue and the radiation field; warm and loosen tissue that borders the fibrotic zone [post-healing only — skip during active treatment]
- Radiation field myofascial work — gentle, sustained pressure and slow myofascial stretching within the field; work within tissue tolerance; fibrotic tissue responds slowly to sustained load; cross-fiber technique where tissue layers are adhered [post-healing only; confirmed skin integrity required]
- ROM work at affected joints — gentle passive mobilization through available range; document gains; fibrosis limits gains per session but consistent treatment over weeks produces measurable improvement
- Lymphedema management — if downstream limb is at risk or affected, incorporate MLD principles (light pressure, proximal-to-distal clearing); separate from fibrosis treatment in technique and pressure
- Reassess ROM and tissue mobility — compare to pre-treatment baseline; document for progress tracking
Adjunct Modalities
- Hydrotherapy: warm moist heat to fibrotic tissue before myofascial work (post-healing only) to improve tissue pliability; avoid heat during active treatment; cool compresses for reactive skin during treatment; always confirm intact sensation before thermal application
- Joint mobilization: gentle glenohumeral mobilization (inferior and posterior glide) if shoulder ROM is restricted by chest wall fibrosis — performed after soft tissue release; Grade I–II only; avoid mobilization of irradiated bone directly; cervical mobilization for head/neck fields only if Lhermitte's sign is negative
- Remedial exercise (on-table): active-assisted ROM to reinforce gains from myofascial work; sustained end-range stretching (30-second holds) to promote fibrotic tissue elongation; jaw opening exercises for trismus (head/neck fields)
Exam Station Notes
- Demonstrate field identification as the first assessment step — ask about treatment location, check for ink marks and tattoos, assess skin integrity
- Verbalize that the field is a local contraindication during active treatment and until skin heals
- Show awareness of bone fragility — state that you would use conservative pressure over irradiated ribs or bones
- Demonstrate awareness of lubricant restriction during active treatment — verbalize that no products would be applied to the field without oncologist approval
Verbal Notes
- Field identification: "Before we start, can you show me or describe where your radiation treatment was targeted? I'm looking for any ink marks or tattoo dots on your skin that show the treatment area. I need to know exactly where the field is so I can work safely."
- Post-healing field work: "Now that your skin has fully healed from radiation, I'd like to start working on the area to help improve the tissue flexibility. The radiation can cause the tissue to tighten over time, and gentle manual work can help slow that process. It may feel like firm tissue under my hands — that's the fibrotic changes from the treatment."
- Ink marks: "I can see the marks on your skin from the radiation targeting. I won't touch or try to remove those — they're important for your treatment team."
Self-Care
- Daily gentle stretching of ROM at joints crossed by the radiation field — sustained holds (30 seconds), 3–5 repetitions, 2–3 times daily; consistency is critical to slow fibrosis progression
- Moisturize the healed radiation field daily with gentle, fragrance-free lotion to maintain skin integrity
- Sun protection for irradiated skin (SPF 30+ or physical coverage) — irradiated skin is permanently more sensitive to UV damage
- Meticulous skin care on the at-risk limb if nodal irradiation was performed — lymphedema prevention measures (avoid cuts, insect bites, blood pressure cuffs on the affected arm)
Key Takeaways
- The radiation field is a local contraindication during treatment and until the skin fully heals; ink/tattoo targeting marks must never be removed
- Radiation fibrosis develops months to years post-treatment and is progressive — dense, contracted, inelastic tissue restricting ROM; gentle myofascial work may reduce restriction once healing is complete
- Lymphedema is a permanent risk after nodal irradiation — additive with surgical node removal; treat downstream limbs conservatively
- Irradiated bone has increased fracture risk — use conservative pressure over bones in the field; avoid aggressive mobilization
- Brachial plexopathy after breast/axillary radiation: upper trunk (C5–C6, initially painless) = radiation damage; lower trunk (C8–T1, painful) = suspect tumor recurrence — both require medical investigation
- Radiation recall can trigger inflammatory skin reactions in the field weeks to months after radiation ends, triggered by certain chemotherapy drugs — this is a local contraindication
- Cumulative fatigue peaks 1–2 weeks after the final fraction; shorter sessions are essential during active treatment